Cost of Intralesional Collagenase Clostridium Histiolyticum Therapy Versus Surgery for the Management of Peyronie's Disease: A Claims-Based Analysis (2009–2019)

BACKGROUND: Collagenase Clostridium histolyticum (CCH), which was approved by the FDA for the treatment of Peyronie's disease (PD) in 2013, may obviate the need for surgery but its historically high cost must be considered when offering CCH vs surgical intervention to affected patients. AIM: To...

Descripción completa

Detalles Bibliográficos
Autores principales: Walton, Eric L., Quinn, Timothy P., Mulloy, Evan, Patil, Dattatraya, Mehta, Akanksha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177867/
https://www.ncbi.nlm.nih.gov/pubmed/35461065
http://dx.doi.org/10.1016/j.esxm.2022.100517

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177867/
https://www.ncbi.nlm.nih.gov/pubmed/35461065
http://dx.doi.org/10.1016/j.esxm.2022.100517

Ejemplares similares